Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401182 | 1.00 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL6889085 | 1.00 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL29458423 | 1.00 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL1660910 | 0.99 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL230688 | 0.94 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29468684 | 0.94 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31031901 | 0.94 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.94 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL163534 | 0.89 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL15160681 | 0.88 | KMT2A (0.75) | KMT2AEPHX2FABP7FABP5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12467085-B2 | High accuracy nanopore-based single molecule sequencing by synthesis with tagged nucleotides | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| US-20240209432-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4303314-A2 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | F. Hoffmann-La Roche AG (CH) | 2024-01-10 | — | — | EP | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11739378-B2 | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | Roche Sequencing Solutions, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20040253181-A1 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET (FR) | 2004-12-16 | — | — | US | disclosed |
| WO-2004058275-A2 | COMPOSITIONS OF MAGNETIC PARTICLES COVERED WITH GEM-BISPHOSPHONATE DERIVATIVES | GUERBET (FR) | 2004-07-15 | — | — | WO | disclosed |
| EP-0643778-B1 | ENCODED COMBINATORIAL CHEMICAL LIBRARIES | SCRIPPS RESEARCH INST (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0647133-A4 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. | AFFYMAX TECH NV (AN) | 1997-10-29 | — | — | EP | disclosed |
| US-5607691-A | IONTOPHORESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-03-04 | — | — | US | disclosed |
| EP-0643778-A4 | ENCODED COMBINATORIAL CHEMICAL LIBRARIES. | SCRIPPS RESEARCH INST (US) | 1995-09-20 | — | — | EP | disclosed |
| EP-0647133-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-04-12 | — | — | EP | disclosed |
| EP-0643778-A1 | ENCODED COMBINATORIAL CHEMICAL LIBRARIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993025197-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-12-23 | — | — | WO | disclosed |
| WO-1993020242-A1 | ENCODED COMBINATORIAL CHEMICAL LIBRARIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739378-B2 | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | NPPA, ANPEP, TENT4A | KMT2A 3667/4885EPHX2 4673/4885FABP7 1315/4885 |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | KMT2A 3463/4885EPHX2 1615/4885FABP7 820/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | KMT2A 2167/4885EPHX2 2080/4885FABP7 1242/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
| US-20240209432-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | NPPA, ANPEP, TENT4A | KMT2A 3667/4885EPHX2 4673/4885FABP7 1315/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.